Practical guidance on the use of sacubitril/valsartan for heart failure
Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that has
been recommended in clinical practice guidelines to reduce morbidity and mortality in …
been recommended in clinical practice guidelines to reduce morbidity and mortality in …
[HTML][HTML] 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of …
The American College of Cardiology (ACC) has a long history of develo** documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …
decision pathways, health policy statements, appropriate use criteria) to provide members …
The role of angiotensin receptor–neprilysin inhibitors in cardiovascular disease—existing evidence, knowledge gaps, and future directions
Although traditional renin–angiotensin system antagonists including angiotensin‐converting
enzyme inhibitors and angiotensin receptor blockers have revolutionized the treatment of …
enzyme inhibitors and angiotensin receptor blockers have revolutionized the treatment of …
Comparison of the efficacy and safety of sacubitril/valsartan versus ramipril in patients with ST-segment elevation myocardial infarction
The role of sacubitril and/or valsartan in patient with heart failure (HF) is established.
Whether sacubitril and/or valsartan plays a role in improving outcomes in patients after ST …
Whether sacubitril and/or valsartan plays a role in improving outcomes in patients after ST …
Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The …
Importance In May 2020, dapagliflozin was approved by the US Food and Drug
Administration (FDA) as the first sodium-glucose cotransporter 2 inhibitor for heart failure …
Administration (FDA) as the first sodium-glucose cotransporter 2 inhibitor for heart failure …
Patient eligibility for established and novel guideline-directed medical therapies after acute heart failure hospitalization
N Moghaddam, NM Hawkins, R McKelvie, S Poon… - Heart Failure, 2023 - jacc.org
Background Acute heart failure (AHF) hospitalization presents an opportunity to optimize
pharmacotherapy to improve outcomes. Objectives This study's aim was to define eligibility …
pharmacotherapy to improve outcomes. Objectives This study's aim was to define eligibility …
Sacubitril/valsartan eligibility and outcomes in the ESC‐EORP‐HFA Heart Failure Long‐Term Registry: bridging between European Medicines Agency/Food and Drug …
CJ Kapelios, M Lainscak, G Savarese… - European journal of …, 2019 - Wiley Online Library
Aims To assess the proportion of patients with heart failure and reduced ejection fraction
(HFrEF) who are eligible for sacubitril/valsartan (LCZ696) based on the European Medicines …
(HFrEF) who are eligible for sacubitril/valsartan (LCZ696) based on the European Medicines …
Guideline-directed medical therapy for the treatment of heart failure with reduced ejection fraction
J Patel, N Rassekh, GC Fonarow, P Deedwania… - Drugs, 2023 - Springer
Guideline-directed medical therapy (GDMT) is the cornerstone of pharmacological therapy
for patients with heart failure with reduced ejection fraction (HFrEF) and consists of the four …
for patients with heart failure with reduced ejection fraction (HFrEF) and consists of the four …
Effects of sacubitril/valsartan on functional status and exercise capacity in real-world patients
CW Lau, P Martens, S Lambeets, M Dupont… - Acta …, 2019 - Taylor & Francis
Background: Sacubitril/valsartan significantly reduced heart failure (HF) hospitalisations and
mortality in the PARADIGM-HF-trial. However real-world data on symptomatic and functional …
mortality in the PARADIGM-HF-trial. However real-world data on symptomatic and functional …
Representativeness of a heart failure trial by race and sex: results from ASCEND-HF and GWTG-HF
Objectives: This study sought to determine the degree to which US patients enrolled in a
heart failure (HF) trial represent patients in routine US clinical practice according to race and …
heart failure (HF) trial represent patients in routine US clinical practice according to race and …